GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Aarti Drugs Ltd

Aarti Drugs Q2 FY27 Consolidated Profit Rises to Rs. 8,277 lakhs

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 03 Nov 2026, 07:03 PM IST  ·  BSE ID: 5936fc36-9e35-42e0-bfd8-b95973b97f35
View Original BSE Filing (PDF)
💡
In Simple Terms
Aarti Drugs announced its financial results, showing an increase in its quarterly consolidated revenue and profit.
🤖 AI Summary
  • Aarti Drugs reported consolidated Revenue from operations of Rs. 82,624 lakhs in Q2 FY27.
  • Consolidated Net Profit after tax for Q2 FY27 reached Rs. 8,277 lakhs.
  • Standalone Revenue from operations stood at Rs. 70,628 lakhs for Q2 FY27.
  • Standalone Net Profit after tax for Q2 FY27 was Rs. 5,768 lakhs.
  • The Board approved audited financial results for the quarter and half year ended September 30, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Consolidated Revenue from Operations (Q2 FY27)
82,624 lakhs
26.57%
Consolidated Net Profit (Q2 FY27)
8,277 lakhs
83.27%
Standalone Revenue from Operations (Q2 FY27)
70,628 lakhs
22.17%
Standalone Net Profit (Q2 FY27)
5,768 lakhs
37.76%
Consolidated Total Assets (30 Sep 2026)
3,05,372 lakhs
🏢 How This Affects the Company
📈
Business Impact
Consolidated revenue from operations increased by Rs. 17,345 lakhs from Q2 FY26 to Q2 FY27, indicating growth in its core pharmaceutical business.
💰
Financial Impact
Consolidated Net Profit after Tax increased to Rs. 8,277 lakhs in Q2 FY27 from Rs. 4,516 lakhs in Q2 FY26, strengthening the company's profitability. Total consolidated assets increased from Rs. 2,81,526 lakhs as of March 31, 2026, to Rs. 3,05,372 lakhs as of September 30, 2026.
⚙️
Operational Impact
The increase in cost of materials consumed and other expenses aligns with increased revenue, suggesting higher operational activity and scale.
⚠️
Risk Impact
The company's non-current borrowings decreased from Rs. 25,687 lakhs (31 Mar 2026) to Rs. 23,950 lakhs (30 Sep 2026) consolidated, indicating some debt reduction.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the increase in consolidated net profit to Rs. 8,277 lakhs for Q2 FY27.
🔍
Management Signal
The timely release of audited financial results reflects management's adherence to regulatory compliance and commitment to transparency.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — check for sustained revenue growth and profitability.
Investor conference call details — understand management commentary on performance.
Updates on material costs — monitor impact on gross margins.
LOW RISK Financial results show growth in key metrics with unmodified audit opinions.
💡 Investor Takeaway
Aarti Drugs reported consolidated Q2 FY27 Revenue from Operations of Rs. 82,624 lakhs, a 26.57% increase YoY. Consolidated Net Profit after Tax rose to Rs. 8,277 lakhs, up 83.27% from Rs. 4,516 lakhs in Q2 FY26. Standalone Net Profit after Tax increased to Rs. 5,768 lakhs, up 37.76% YoY from Rs. 4,188 lakhs.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Profit After Tax for Q2 FY27 increased to Rs. 8,277 lakhs, up from Rs. 4,516 lakhs in Q2 FY26.
  • Consolidated Revenue from Operations for Q2 FY27 grew to Rs. 82,624 lakhs compared to Rs. 65,279 lakhs in Q2 FY26.

⚠️ Concerns

  • Consolidated purchase of stock-in-trade decreased to Rs. 3,313 lakhs in Q2 FY27 from Rs. 3,064 lakhs in Q2 FY26.
  • Standalone Cash Flow from Operating Activities decreased to Rs. 3,393 lakhs for H1 FY27, from Rs. 14,992 lakhs for H1 FY26.
📅 Company Track Record
Aarti Drugs' Q1 FY27 consolidated revenue was Rs. 70,358 lakhs, with PAT at Rs. 5,013 lakhs. The current Q2 FY27 results show sequential growth in both consolidated revenue and PAT.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Aarti Drugs' consolidated net profit for Q2 FY27?
Aarti Drugs reported a consolidated net profit of Rs. 8,277 lakhs for the quarter ended September 30, 2026 (Q2 FY27).
What was Aarti Drugs' consolidated revenue from operations for Q2 FY27?
The consolidated revenue from operations for Aarti Drugs in Q2 FY27 was Rs. 82,624 lakhs.
How did Aarti Drugs' standalone net profit compare year-over-year in Q2 FY27?
Aarti Drugs' standalone net profit for Q2 FY27 was Rs. 5,768 lakhs, representing a 37.76% increase compared to Rs. 4,188 lakhs in Q2 FY26.
What were Aarti Drugs' consolidated total assets as of September 30, 2026?
Aarti Drugs reported consolidated total assets of Rs. 3,05,372 lakhs as of September 30, 2026.
When did the Board meeting conclude for Aarti Drugs' Q2 FY27 results?
The Board of Directors meeting for Aarti Drugs concluded at 4:20 PM on November 3, 2026, after approving the Q2 FY27 results.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.